New Tx Approach for Immunotherapy-Induced Myocarditis New Tx Approach for Immunotherapy-Induced Myocarditis
A novel combination of high-dose abatacept, ruxolitinib, and mechanical ventilation markedly improved immunotherapy-induced myocarditis survival over current guideline-recommended treatment.Medscape Medical News
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Hematology-Oncology News Source Type: news
More News: Abatacept | Cancer & Oncology | Hematology | Immunotherapy | Intensive Care | Myocarditis | Orencia